Vitamin D postpones the progression of epithelial ovarian cancer induced by 7, 12-dimethylbenz [a] anthracene both in vitro and in vivo

Purpose: Ovarian cancer is the most lethal malignancy of the female reproductive system, and the prevention and treatment of ovarian carcinoma are still far from optimal. Epidemiological studies reported that ovarian cancer risk was inversely associated with low level of 25-hydroxy vitamin D [25(OH)]. Therefore, this study focuses on exploring the chemoprevention of vitamin D on epithelial ovarian cancer induced by 7, 12-dimethylbenz [a] anthracene (DMBA). Methods: The mouse ovarian surface epithelial cells were isolated from estrus mice by mild trypsinization and maintained in completed culture medium by repeated passaging. The malignant transformation of mouse ovarian surface epithelial cells was induced by DMBA in vitro. DMBA was directly injected into the bursa of mouse ovary to produce optimized in vivo ovarian cancer model. Results: The results indicate that 1 α ,25 dihydroxyvitamin D3 may delay malignant transformation of mouse ovarian surface epithelial cells induced by DMBA and significantly decreased the colony formation rate from 18.4% to 3.2% ( P , 0.05). There was a negative correlation between incidence of DMBA-induced tumor and 25-hydroxy vitamin D level ( R 2 = 0.978, P , 0.05). Vitamin D3 can delay the progression of ovarian cancer induced by DMBA, and the administration of vitamin D3 during the whole process worked more effectively than the administration only during tumor initiation or promotion. Moreover, we found the vitamin D3 increased the expression of E-cadherin and vitamin D receptor while it decreased the expression of β -catenin. Conclusion: We succeeded in establishment of epithelial ovarian cancer models both in vitro and in vivo. The DMBA-implanted model in mice yields high incidence and specificity of epithelial derived tumors. We also found that vitamin D delays the progression of ovarian cancer. However, spontaneous epithelial ovarian carcinoma models are still to be explored for testing the preventive effects of vitamin D on epithelial ovarian cancer.

[1]  Guangming Zhou,et al.  Vitamin D postpones the progression of epithelial ovarian cancer induced by 7, 12-dimethylbenz [a] anthracene both in vitro and in vivo , 2016, OncoTargets and therapy.

[2]  P. Hershberger,et al.  Vitamin D Repletion Reduces the Progression of Premalignant Squamous Lesions in the NTCU Lung Squamous Cell Carcinoma Mouse Model , 2015, Cancer Prevention Research.

[3]  P. Webb,et al.  Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. , 2015, The American journal of clinical nutrition.

[4]  S. Nicosia,et al.  Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  ping wang,et al.  Synergy of 1,25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells , 2014, Oncology letters.

[6]  E. Giovannucci,et al.  The role of vitamin D in reducing cancer risk and progression , 2014, Nature Reviews Cancer.

[7]  Marcelo Martinez,et al.  Characterization of Chemically Induced Ovarian Carcinomas in an Ethanol-Preferring Rat Model: Influence of Long-Term Melatonin Treatment , 2013, PloS one.

[8]  D. Feldman,et al.  Equivalent anticancer activities of dietary vitamin D and calcitriol in an animal model of breast cancer: Importance of mammary CYP27B1 for treatment and prevention , 2013, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  J. Marks,et al.  Vitamin D receptor (VDR) polymorphisms and risk of ovarian cancer in Caucasian and African American women. , 2013, Gynecologic oncology.

[10]  P. Jagodziński,et al.  Vitamin D receptor gene BsmI and FokI polymorphisms in relation to ovarian cancer risk in the Polish population. , 2013, Genetic testing and molecular biomarkers.

[11]  Jennifer M. Watson,et al.  7,12-dimethylbenz[a]anthracene-induced malignancies in a mouse model of menopause. , 2013, Comparative medicine.

[12]  N. Núñez,et al.  Using components of the vitamin D pathway to prevent and treat colon cancer. , 2012, Nutrition reviews.

[13]  Yiping Huang,et al.  Enhanced efficacy and specificity of epithelial ovarian carcinogenesis by embedding a DMBA-coated cloth strip in the ovary of rat , 2012, Journal of Ovarian Research.

[14]  C. McCarty,et al.  Diabetes prevalence is associated with serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in US middle-aged Caucasian men and women: a cross-sectional analysis within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. , 2011, The British journal of nutrition.

[15]  H. Brenner,et al.  Meta-analysis: Circulating vitamin D and ovarian cancer risk. , 2011, Gynecologic oncology.

[16]  D. Armstrong,et al.  Recent progress in the diagnosis and treatment of ovarian cancer , 2011, CA: a cancer journal for clinicians.

[17]  W. Grant.  Good evidence exists that solar ultraviolet-B and vitamin D reduce the risk of ovarian cancer. , 2010, American journal of obstetrics and gynecology.

[18]  M. Lehtinen,et al.  Independent and joint effects of serum 25-hydroxyvitamin D and calcium on ovarian cancer risk: a prospective nested case-control study. , 2010, European journal of cancer.

[19]  Rakesh K. Singh,et al.  Chemotherapeutic Effect of Calcidiol Derivative B3CD in a Neuroblastoma Xenograft Model , 2010, Chemical biology & drug design.

[20]  H. Cross,et al.  Calcium, vitamin D and cancer. , 2009, Anticancer research.

[21]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[22]  N. Weigel,et al.  Androgen receptor signaling and vitamin D receptor action in prostate cancer cells , 2005, The Prostate.

[23]  F. Gonzalez,et al.  Mechanism of 7,12-dimethylbenz[a]anthracene-induced immunotoxicity: role of metabolic activation at the target organ. , 2001, Japanese journal of pharmacology.

[24]  J L Pace,et al.  Development of a syngeneic mouse model for events related to ovarian cancer. , 2000, Carcinogenesis.

[25]  Y. Oshika,et al.  P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. , 1996, British Journal of Cancer.

[26]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[27]  M. Lehtinen,et al.  Serum 25-hydroxyvitamin D and the risk of ovarian cancer. , 2010, European journal of cancer.

[28]  A. Kinsella,et al.  Cadherin–catenin expression in primary colorectal cancer: a survival analysis , 1999, British Journal of Cancer.